Nymox Reports 2011 Financial Results
March 15 2012 - 9:34AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its
financial results for the year ended December 31, 2011 prepared in
accordance with International Financial Reporting Standards. Nymox
reported a net loss of $9,652,389, or $0.30 per share for the year
ended December 31, 2011, compared to $6,536,313, or $0.20 per share
for same period in 2010. The increase of the net loss for the year
is attributable primarily to stock-based compensation charges which
were $4,005,404 in 2011 compared to $478,865 in 2010. The weighted
average number of common shares outstanding for the year ended
December 31, 2011 was 32,711,431, compared to 31,940,584 for the
same period in 2010.
Revenues from sales amounted to $496,215 for the year ended
December 31, 2011, compared to $582,383 for the same period in
2010. The decrease in sales is attributed to a large number of
orders by one client for NicAlertâ„¢ and TobacAlertâ„¢ in 2010 which
were not repeated in 2011. Additionally, an amount of $2,617,600
was recognized as revenue relating to the upfront payment received
from Nymox's licensing agreement with Recordati in December 2011
compared to $109,067 recognized in 2010.
Nymox Pharmaceutical Corporation is engaged in the research and
development of therapeutics and diagnostics, with a particular
emphasis on products targeted for the unmet needs of the aging
population. The Company's new drug for benign prostatic hyperplasia
(BPH) is in Phase 3 development in the U.S. and Europe. Currently
Nymox has three products on the market, and a healthy pipeline of
drug and diagnostic products. The Company also has several hundred
patents and patent applications.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024